Quebec, Canada
Quebec, Canada

Æterna Zentaris Inc. is a Quebec, Canada-based biopharmaceutical drug development company focused in oncology and endocrine therapy, currently investigating treatments for various unmet medical needs. The Company's pipeline encompasses compounds at all stages of development, from drug discovery through to marketed products. It has over 80 employees in Canada, USA and Germany. The company is based in Canada, the development and research site is based in Germany. The company has 3 lead projects: an ongoing Phase 3 trial in multiple myeloma conducted under a Special Protocol Assessment : a Phase 3 trial in endometrial cancer with AEZS-108 expected to be initiated in 1Q 2013, and a New Drug Application expected to be filed in 1Q 2013 for the approval of AEZS-130 as potentially the first oral diagnostic test for adult growth hormone deficiency .Perifosine: Fast track designation and orphan drug status granted by the FDA. Orphan Medicinal Product designation and positive Scientific Advice granted by the EMA .AEZS-108: Orphan drug and Orphan medicinal product designations granted by the FDA and EMA respectively, for the treatment of ovarian cancer.AEZS-130: Orphan drug designation granted by the FDA for use as a diagnostic test for AGHD. Wikipedia.


Time filter

Source Type

Patent
AEterna Zentaris, Montpellier University and French National Center for Scientific Research | Date: 2011-09-16

The present invention provides novel triazole derivatives with improved receptor activity and bioavailability properties as ghrelin analogue ligands of growth hormone secretagogue receptors according to formula (I) that are useful in the treatment or prophylaxis of physiological and/or pathophysiological conditions in mammals, preferably humans, that are mediated by GHS receptors. The present invention further provides GHS receptor antagonists and agonists that can be used for modulation of these receptors and are useful for treating above conditions, in particular alcohol disorder, drug abuse, growth retardation, cachexia, short-, medium-, and/or long term regulation of energy balance, short-, medium-, and/or long term regulation (stimulation and/or inhibition) of food intake, intake of rewarding food, adipogenesis, adiposity and/or obesity, body weight gain and/or reduction, diabetes, diabetes type I, diabetes type II, tumor cell proliferation, inflammation, inflammatory effects, gastric postoperative ileus, postoperative ileus and/or gastrectomy (ghrelin replacement therapy).


Patent
AEterna Zentaris | Date: 2012-04-04

The present invention provides new pyridopyrazine compounds which are suitable for the treatment or prevention of physiological and/or pathophysiological states mediated and/or modulated by signal transduction pathways and/or enzymes in mammals and in particular in humans.


Patent
AEterna Zentaris | Date: 2012-04-04

The present invention provides new pyridopyrazine compounds which are suitable for the treatment or prevention of physiological and/or pathophysiological states mediated and/or modulated by signal transduction pathways and/or enzymes in mammals and in particular in humans.


The invention relates to pyrido[2,3-b]pyrazine compounds of general formulae (Ia) and (Ib), to their preparation and use, for example, for the treatment of malignant disorders and other disorders based on pathological cell proliferations.


The invention relates to an non-pathogenic and/or attenuated bacterium which is capable of inducing apoptosis in macrophages.


The invention relates to pyrido[2,3-b]pyrazine compounds of general formulae (Ia) and (Ib), to their preparation and use, for example, for the treatment of malignant disorders and other disorders based on pathological cell proliferations.


LHRH analogues and LHRH antagonists for use in the treatment or prophylaxis of hormone-dependent cancers, in particular prostate cancer, prostate carcinoma and/or advanced prostate carcinoma, by administering an initial dose of an LHRH analogue over a first period sufficient to effect hormonal castration, then administering a maintenance dose of an LHRH antagonist over a second period, the dose being insufficient to achieve and/or maintain hormonal castration.


The present invention describes a process for the selective synthesis of N-Fmoc-doxorubicin-14-O-dicarboxylic acid mono ester derivatives starting from N-Fmoc-doxorubicin using lipase enzymes and bis-acyl donor compounds such as dicarboxylic acids or anhydrides.


The present invention provides novel tetrahydrocarbazole compounds according to formula (I) as ligands of G-protein coupled receptors (GPCR) which are useful in the treatment and/or prophylaxis of physiological and/or pathological conditions in mammals mediated by GPCR or of physiological and/or pathological conditions which can be treated by modulation of these receptors.


The invention relates to pyrido[2,3-b]pyrazine compounds of general formulae (Ia) and (Ib), to their preparation and use, for example, for the treatment of malignant disorders and other disorders based on pathological cell proliferations.

Loading AEterna Zentaris collaborators
Loading AEterna Zentaris collaborators